Abatacept for Lung Disease in Common Variable Immunodeficiency
This study is testing a drug called abatacept (also known as Orencia) for people with Common Variable Immunodeficiency (CVID) who also have a type of lung disease called Interstitial Lung Disease (ILD). Abatacept works by blocking certain signals that activate immune cells (T lymphocytes). Currently, there isn't a standard treatment for this condition. Researchers want to see if abatacept can improve lung health compared to a placebo (an inactive substance). You might be able to join if you are at least 4 years old and have a confirmed diagnosis of CVID. The main way they will measure success is by looking at changes in your lungs using a special CT scan after 6 months.
- Study design
- This is a multi-site, randomized, blinded study comparing abatacept to a placebo, with some participants receiving abatacept openly. It plans to enroll 38 participants, including children and adults.
- What's involved
- Participants will receive treatment for 12 months, with the option to continue abatacept for up to 3 years. The primary outcome will be measured at 6 months using a High Resolution CT Scan of the chest.
- Compensation
- Not stated in the trial record.
- Follow-up
- After the initial 12 months of treatment, patients have the option to continue abatacept for up to 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
At a glance
Conditions
Where it's being run
6 sites across 6 statesStudy leadership
- Michael Jordan · PRINCIPAL_INVESTIGATOR · Children's Hospital Medical Center, Cincinnati
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- High Resolution CT Scan of the chest (HRCT)6 months
Proportion of subjects achieving a significant response (defined as \>30 percent change in lung tissue disease burden by GLILD) on HRCT after 6 months of abatacept therapy.